CONSTANT LEVERAGE LONG - MODERNA | Market Closed - Euronext Paris 10:00:02 15/05/2024 pm IST | ||
| 0.022 EUR | -8.33% |
|
| Current month | +50.00% | ||
| 1 month | +90.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 15/24/15 | 0.022 | -8.33% |
| 14/24/14 | 0.024 | +20.00% |
| 13/24/13 | 0.02 | +25.00% |
| 10/24/10 | 0.016 | -23.81% |
| 09/24/09 | 0.021 | +10.53% |
Real-time Euronext Paris
Last update May 15, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| F84JB | |
| ISIN | FRBNPP059497 |
| Date issued | 05/01/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 4.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.175 € |
|---|---|
| Lowest since issue | 0.002 € |
| Spread | 0.001 € |
| Spread % | 4.35% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
128.3
USD
Average target price
138.5
USD
Spread / Average Target
+7.94%
- Stock Market
- Certificates
- F84JB Certificat